Q4 2025 Management View CEO Lishan Aklog reported that "our EsoGuard test volume in the fourth quarter was 3,664. That exceeds our target range that we've articulated regularly of approximately 2,500 ...
GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow ...
Chris Hall, President and CEO, highlighted, "2025 was the year we validated our winning MRD strategy. 2026 is the year we expect to scale. Physicians increasingly trust our NeXT Personal test. Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results